WASHINGTON, DC – The Subcommittee on Health, chaired by Rep. Michael C. Burgess, M.D. (R-TX), announced a hearing for Tuesday, October 3, 2017, at 10:15 a.m. in room 2322 of the Rayburn House Office Building. The hearing is entitled, “Examining Patient Access to Investigational Drugs.”
#SubHealth will discuss patient access to investigational drugs and the U.S. Food and Drug Administration’s (FDA) expanded access program, which is designed to help patients who do not qualify for clinical trials to access unapproved therapies. The subcommittee will also discuss legislation related to access to unapproved therapies.
“This is an important conversation to have, particularly as states across the country have begun exploring ‘Right to Try’ laws. Our subcommittee will hear from stakeholders interested in improving patient access to unapproved therapies,” said Dr. Burgess. “I look forward to a productive discussion and feedback from both stakeholders and government officials about the best path forward.”
The Majority Memorandum, witness list, and witness testimony for the hearing will be available here as they are posted.